company background image
A085

CHA Biotech KOSDAQ:A085660 Stock Report

Last Price

₩17.40k

Market Cap

₩979.1b

7D

0%

1Y

-9.1%

Updated

22 May, 2022

Data

Company Financials
A085660 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

A085660 Stock Overview

CHA Biotech Co., Ltd., together with its subsidiaries, engages in cell therapy development, cord blood, and stem cell banking services.

CHA Biotech Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for CHA Biotech
Historical stock prices
Current Share Price₩17,400.00
52 Week High₩31,100.00
52 Week Low₩15,500.00
Beta1.03
1 Month Change-6.45%
3 Month Change4.82%
1 Year Change-9.14%
3 Year Change6.75%
5 Year Change39.76%
Change since IPO133.13%

Recent News & Updates

Mar 01
Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?

Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Jan 25
If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%

If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%

CHA Biotech Co., Ltd. ( KOSDAQ:085660 ) shareholders should be happy to see the share price up 19% in the last quarter...

Shareholder Returns

A085660KR HealthcareKR Market
7D0%7.5%1.6%
1Y-9.1%-39.9%-14.2%

Return vs Industry: A085660 exceeded the KR Healthcare industry which returned -39.9% over the past year.

Return vs Market: A085660 exceeded the KR Market which returned -14.2% over the past year.

Price Volatility

Is A085660's price volatile compared to industry and market?
A085660 volatility
A085660 Average Weekly Movement4.5%
Healthcare Industry Average Movement5.8%
Market Average Movement5.5%
10% most volatile stocks in KR Market10.4%
10% least volatile stocks in KR Market3.2%

Stable Share Price: A085660 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: A085660's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002205n/ahttps://www.chabio.com

CHA Biotech Co., Ltd., together with its subsidiaries, engages in cell therapy development, cord blood, and stem cell banking services. The company operates a cord blood consignment storage business for the treatment of intractable diseases, as well as provides regenerative medicines, Immune and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs comprising fitness, spa, and supplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It also offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare.

CHA Biotech Fundamentals Summary

How do CHA Biotech's earnings and revenue compare to its market cap?
A085660 fundamental statistics
Market Cap₩979.07b
Earnings (TTM)-₩21.37b
Revenue (TTM)₩747.67b

1.3x

P/S Ratio

-45.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A085660 income statement (TTM)
Revenue₩747.67b
Cost of Revenue₩534.15b
Gross Profit₩213.51b
Other Expenses₩234.88b
Earnings-₩21.37b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-379.72
Gross Margin28.56%
Net Profit Margin-2.86%
Debt/Equity Ratio41.6%

How did A085660 perform over the long term?

See historical performance and comparison

Valuation

Is CHA Biotech undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.11x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A085660's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A085660's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: A085660 is unprofitable, so we can't compare its PE Ratio to the Asian Healthcare industry average.

PE vs Market: A085660 is unprofitable, so we can't compare its PE Ratio to the KR market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A085660's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: A085660 is good value based on its PB Ratio (2.1x) compared to the KR Healthcare industry average (2.3x).


Future Growth

How is CHA Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


16.6%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CHA Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has CHA Biotech performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-4.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A085660 is currently unprofitable.

Growing Profit Margin: A085660 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: A085660 is unprofitable, and losses have increased over the past 5 years at a rate of 4.3% per year.

Accelerating Growth: Unable to compare A085660's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A085660 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (33.2%).


Return on Equity

High ROE: A085660 has a negative Return on Equity (-4.21%), as it is currently unprofitable.


Financial Health

How is CHA Biotech's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: A085660's short term assets (₩577.5B) exceed its short term liabilities (₩414.7B).

Long Term Liabilities: A085660's short term assets (₩577.5B) exceed its long term liabilities (₩354.3B).


Debt to Equity History and Analysis

Debt Level: A085660 has more cash than its total debt.

Reducing Debt: A085660's debt to equity ratio has increased from 27.5% to 41.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A085660 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: A085660 has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 37% each year.


Dividend

What is CHA Biotech current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A085660's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A085660's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A085660's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A085660's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A085660 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

CHA Biotech has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.5%.


Top Shareholders

Company Information

CHA Biotech Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: CHA Biotech Co., Ltd.
  • Ticker: A085660
  • Exchange: KOSDAQ
  • Founded: 2002
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Implied Market Cap: ₩979.069b
  • Shares outstanding: 56.27m
  • Website: https://www.chabio.com

Number of Employees


Location

  • CHA Biotech Co., Ltd.
  • CHA Bio Complex
  • 335 Pangyoro
  • Seongnam-si
  • Gyeonggi-do
  • South Korea

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/22 00:00
End of Day Share Price2022/05/20 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.